Cellectis S.A.
lasme-cel
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Countdown
543days
Approval decision · ~ Jan 1, 2028 estimated
What's at stake
A final FDA approval decision on lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) is expected ~ Jan 1, 2028.
Primary source
· SEC 6-K
verified 11h ago
“Cellectis anticipates submitting a Biologics License Application (BLA) in 2028.”